BofA reinstated coverage of Gilead (GILD) with a Buy rating and $109 price target The investment case is “simple,” namely that Gilead is a relatively “quiet” stock with above-average, durable long-term growth, trading a below-average multiple, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead’s Kite announces results from 5-year follow-up study of Yescarta in NHL
- Gilead price target raised to $115 from $105 at Oppenheimer
- Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole
- Gilead enters ADC option and license pact with Tubulis, sees dilution
- Gilead announces PURPOSE 2 trial data published in NEJM